SCHEMBL2845153

SCHEMBL2845153

CNC(=O)c1cncc(Oc2ccc3nc(NCC4CCCCC4)sc3c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 6/20 0.50
PDGFRB P09619 1/20 0.50
KIT P10721 1/20 0.50
PDGFRA P16234 1/20 0.50
FLT3 P36888 1/20 0.50
RAF1 P04049 4/20 0.46
BRAF P15056 4/20 0.46
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 4/20 0.43
PKM P14618 1/20 0.43
TP53 P04637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
ITK Q08881 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2840488 0.86 CSF1R (0.56) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2842436 0.85 CSF1R (0.49) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2676259 0.84 CSF1R (0.70) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2677847 0.84 CSF1R (0.70) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2845186 0.84 CSF1R (0.49) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2845178 0.84 CSF1R (0.49) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2840489 0.83 CSF1R (0.73) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2840848 0.82 CSF1R (0.47) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2676217 0.79 CSF1R (0.68) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2848586 0.79 NPC1 (0.45) CSF1RPDGFRBKITPDGFRAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885PDGFRB 119/4885KIT 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.